Bain Capital Life Sciences Investors, LLC Crinetics Pharmaceuticals, Inc. Transaction History

Bain Capital Life Sciences Investors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$16.49 - $27.64 $4.55 Million - $7.62 Million	275,857 Added 13.59%	2,305,558 $43 Million
Q4 2021 Feb 14, 2022	BUY	$19.35 - $28.41 $6.77 Million - $9.94 Million	350,000 Added 20.84%	2,029,701 $57.7 Million
Q2 2021 Aug 16, 2021	BUY	$15.9 - $21.15 $9.67 Million - $12.9 Million	608,273 Added 56.77%	1,679,701 $31.7 Million
Q2 2020 Aug 14, 2020	BUY	$13.04 - $23.23 $14 Million - $24.9 Million	1,071,428 New	1,071,428 $18.8 Million

241

79.6M

23.3K

44.3K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $3.01B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Bain Capital Life Sciences Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Bain Capital Life Sciences Investors, LLC with notifications on news.